These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 36733485)

  • 1. Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
    Wang Y; Zhang N; Xue J; Zhu C; Wang Y; Zhang L; Yang X; Wang H; Wang S; Chao J; Yang X; Zhao H
    Front Immunol; 2023; 14():1084843. PubMed ID: 36733485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
    Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice.
    Lin LW; Ke K; Chen R; Yang WZ; Huang N; Wu ZZ
    Front Immunol; 2023; 14():1286771. PubMed ID: 38288113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
    Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
    Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer.
    Zhou M; Jin Y; Zhu S; Xu C; Li L; Liu B; Shen J
    Clin Transl Immunology; 2024; 13(1):e1483. PubMed ID: 38223257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC).
    He M; Huang Y; Du Z; Lai Z; Ouyang H; Shen J; Wen D; Li Q; Zhang Y; Wei W; Chen M; Xu L; Kan A; Shi M
    Clin Cancer Res; 2023 Dec; 29(24):5104-5115. PubMed ID: 37819944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer.
    He C; Sun S; Zhang Y; Li S
    J Inflamm Res; 2021; 14():4795-4807. PubMed ID: 34584438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer.
    Qi H; Zhang W; Chen B; Zhan Q; Wang T; Shi H; Liu Y; Wang Y; Zhong M; Shi X; Shen F; Li Q
    Curr Med Res Opin; 2024 Mar; 40(3):441-453. PubMed ID: 38193524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
    Lin J; Yang X; Long J; Zhao S; Mao J; Wang D; Bai Y; Bian J; Zhang L; Yang X; Wang A; Xie F; Shi W; Yang H; Pan J; Hu K; Guan M; Zhao L; Huo L; Mao Y; Sang X; Wang K; Zhao H
    Hepatobiliary Surg Nutr; 2020 Aug; 9(4):414-424. PubMed ID: 32832493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma.
    Song S; Liu Y; Ren Y; Zheng C; Liang B
    Diagn Interv Radiol; 2024 Jun; ():. PubMed ID: 38836437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toripalimab-tpzi.
    Am J Health Syst Pharm; 2024 Apr; 81(8):251-255. PubMed ID: 38153166
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
    Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
    Wang Y; Xun Z; Yang X; Wang Y; Wang S; Xue J; Zhang N; Yang X; Lu Z; Zhou J; Zhou K; Sang X; Zhao H
    Am J Cancer Res; 2023; 13(3):1026-1037. PubMed ID: 37034211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
    Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
    Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.